The GLP-1 Nutrition Gap: Supporting Digestion, Nutrient Status and Muscle During Weight Loss

Could GLP-1 medications be creating a new kind of nutrition challenge?

For many people, these medicines can be transformative, helping to quieten appetite, reduce ‘food noise’ and achieve clinically meaningful weight loss after years of frustration. But when appetite drops sharply, food portions become smaller and digestion slows, the question changes from simply ‘how do I lose weight?’ to ‘how do I make sure my body is still getting what it needs?’

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists are now used by around 1.6 million adults in Great Britain for weight loss.¹ Semaglutide (used in Wegovy and Ozempic) can produce average weight loss of around 15%, while tirzepatide (used in Mounjaro) can reach around 20%.^2,3 These results create a new nutritional priority: protecting the wider health picture while eating considerably less.

How Do GLP-1 And GIP Medications Work?

GLP-1 and GIP are incretin hormones released from the gut after eating. GLP-1 RAs increase glucose-dependent insulin secretion, reduce glucagon, slow gastric emptying and act on appetite-regulating pathways in the brain, helping people feel fuller for longer. Tirzepatide also activates the GIP receptor, further influencing insulin secretion and metabolic regulation.⁴

Reduced hunger, cravings and food preoccupation can be a huge relief, but the same mechanisms can also affect digestion, nutrient intake and body composition.

GLP-1 Side Effects: Digestion Comes First

For people concerned about GLP-1 medication side effects, the first area to consider is digestion. Common gastrointestinal symptoms include nausea, vomiting, constipation, diarrhoea, reflux, bloating, dyspepsia and delayed gastric emptying.^5,6

• Slower gastric emptying means meals sit in the stomach for longer. A portion that once felt normal, may suddenly feel too large, while nausea or early fullness can make it difficult to finish meals. GLP-1 signalling also interacts with vagal pathways and areas of the brain involved in nausea and vomiting and can reduce gastric acid secretion.^6–8
• Gallbladder and biliary health also need consideration. GLP-1 RAs are associated with a modest increase in gallbladder and biliary disease, particularly during weight-loss treatment and at higher doses.⁹ Rapid weight loss itself can contribute, alongside reduced gallbladder motility and altered bile release.
• Acute pancreatitis is a less common but more serious complication. Cases have been reported with GLP-1 medications used for weight loss,¹⁰ and in January 2026 the MHRA strengthened its warnings following rare reports of severe acute pancreatitis.¹¹ Severe, persistent abdominal pain, particularly if it radiates to the back with nausea or vomiting, requires urgent medical assessment. Pancreatic dysfunction can also reduce digestive enzyme activity, and fat-soluble nutrient absorption.

The GLP-1 Nutrition Gap

The body may be receiving less food, but its needs for protein, vitamins and minerals has not disappeared.

People may begin their weight-management journey with suboptimal dietary levels or pre-existing nutrient insufficiencies, particularly where obesity has coexisted with a low-quality diet.¹² Smaller portions, digestive symptoms and less dietary variety may then create further nutritional vulnerability.^13,14

In a study of more than 460,000 adults with type 2 diabetes prescribed GLP-1 RAs, vitamin D was the most commonly recorded deficiency, affecting 7.5% at six months and 13.6% at twelve months. Deficiencies in B vitamins, iron, zinc, magnesium and potassium were also identified.¹³

Fatigue, weakness or dizziness, may be driven by inadequate nutrient intake. Hair loss may also reflect rapid weight loss, physiological stress, reduced protein intake and lower iron and zinc status.^15,16

Protecting Muscle, Not Just Losing Weight

Weight loss is not simply about reducing the number on the scales. Body composition matters.

In a body-composition analysis from the SURMOUNT-1 trial, approximately 75% of weight lost with tirzepatide came from fat mass and 25% from lean mass.¹⁷ The degree of muscle loss differs between individuals, and is influenced by age, baseline muscle reserves, activity, protein intake, and metabolic health.^18,19

Muscle plays an important role in glucose utilisation and insulin sensitivity, while supporting strength, mobility, bone health and healthy ageing. Preserving muscle should therefore be a priority during rapid weight loss, particularly in older adults and those with lower muscle reserves.

What Is Happening to The Microbiome?

The gut microbiome responds very quickly to what we eat. When portion shrink, fibre intake and plant diversity may fall too, changing the substrates available to gut bacteria and potentially reducing short-chain fatty acid (SCFA) production. SCFAs help nourish the gut lining, support intestinal barrier integrity and influence immune function, inflammation, metabolism and healthy bowel function.^20,21

Research suggests GLP-1 medicines can also alter microbial composition, with changes in bacteria such as Akkermansia, Bacteroides and Ruminococcus reported.²⁰ Slower transit, constipation or diarrhoea, alongside less fibre and fewer plant foods, can also change which bacteria thrive and how they function.

Supporting bowel regularity and fibre intake becomes part of GLP-1 nutrition support. However, fibre needs to be introduced according to tolerance, as someone already experiencing nausea, bloating and early fullness may struggle with large volumes of bulky fibre.

Nutritional Priorities During GLP-1 Use

When appetite is low, every meal needs to work a little harder.

Dietary Strategies

• Prioritise protein and nutrient density: When portions are smaller, food quality becomes increasingly important. Protein should be included at each meal where possible, using foods such as eggs, fish, meat, Greek yoghurt, tofu, tempeh, beans and lentil. Protein powders can also be useful when appetite is particularly low. Requirements vary, but the aim is to provide sufficient amino acids to support muscle protein synthesis while weight is coming down.^18,19
• Adapt meals to digestive tolerance: With slower gastric emptying, large or high-fat meals may be more difficult to tolerate. Smaller, regular meals, eating slowly and chewing thoroughly can help with fullness, nausea, bloating and reflux. Ginger and artichoke have been studied together in functional dyspepsia, with improvements in nausea, fullness and bloating.²² Digestive enzymes, including protease, amylase and lipase, support the breakdown of protein, carbohydrate and fat, with multienzyme combinations also showing benefits for meal-related digestive discomfort.²³
• Choose fibre carefully and maintain plant diversity: Partially hydrolysed guar gum (PHGG) is a gentle soluble fibre that is fermented by gut bacteria to produce SCFAs, while also supporting bowel regularity and colonic transit.^24,25 Low-viscosity soluble fibre has also been studied in people with mild-to-moderate gastroparesis, highlighting that fibre type and tolerability can be as important as quantity.²⁶
• Maintaining plant diversity provides both fibre and polyphenols: Berries, citrus fruits, grapes, pomegranate, olives, herbs and green tea contain a diversity of plant compounds that can interact with the microbiome and influence antioxidant, inflammatory and metabolic pathways.²⁷
• Keep hydration in mind: Nausea, vomiting, and diarrhoea can reduce fluid intake. Regular water, herbal teas or diluted fruit or other suitable fluids between meals should form part of everyday support. Where fluid losses are more significant, appropriate electrolyte replacement may be needed rather than relying on water alone.¹⁴

Key Nutrients

When food intake falls, particular attention should be given to nutrients that may already be low or become harder to obtain.

• Fat-soluble vitamins A, D, E and K become particularly relevant when food variety and fat intake are reduced. These vitamins support important functions across immunity, antioxidant protection, vision and bone health. Sources include oily fish, eggs and fortified foods for vitamin D; liver, eggs and orange or dark-green vegetables for vitamin A; nuts, seeds and plant oils for vitamin E; and leafy green vegetables, eggs and fermented foods for vitamin K. Vitamin D supplementation may also be appropriate where intake or status is inadequate.
• Vitamin B12 supports normal red blood cell formation, nervous system function and energy metabolism. It is found mainly in meat, fish, eggs and dairy, while fortified foods or supplementation are important for vegan diets. Long-term metformin use can further increase the risk of low B12.²⁸
• Iron and zinc are also important. Iron contributes to normal red blood cell and haemoglobin formation, while zinc supports normal macronutrient metabolism, immunity and the maintenance of normal hair, skin and nails. Red meat and shellfish are particularly rich sources of both, while eggs, legumes, tofu, nuts and seeds can also contribute. Where iron supplementation is needed, ferrous bisglycinate offer good bioavailability and gastrointestinal tolerability.²⁹
• Magnesium and potassium contribute to normal muscle and nervous system function and electrolyte balance. Magnesium is found in nuts, seeds, legumes, wholegrains and leafy greens, while potatoes, beans, vegetables, fruit and dairy foods can help maintain potassium intake.
• Choline, found in eggs, liver, fish, chicken and soya foods, contributes to normal lipid metabolism and liver function, and is a precursor for phosphatidylcholine, an important component of bile.³⁰

Lifestyle Support

• Protect muscle through movement: Progressive resistance exercise, ideally two to three times per week, alongside regular walking and everyday movement, can help maintain muscle strength and function during weight loss.³¹
• Use quieter appetite to build sustainable habits: One of the most interesting effects of GLP-1 medication is the reduction in ‘food noise’. For many people, fewer cravings and less constant thinking about food can create valuable space to establish new routines.

However, appetite suppression and behavioural change are not the same thing. Hunger and food preoccupation can return when medication is reduced or stopped, and weight regain is common.^32,33 The period on GLP-1 medication can therefore be used to establish habits that support longer-term health, including regular protein intake, balanced meals, fibre, hydration, resistance exercise and good sleep.

It also provides an opportunity to look beyond weight itself. Blood glucose regulation, muscle mass, digestive health, food quality, physical activity and our relationship with hunger and appetite can all influence long-term metabolic health.

Not sure how to support your nutrition while taking GLP-1 medication? Our Clinical Nutrition team can help you understand what your body may need and how to adapt your diet and lifestyle around your individual symptoms and circumstances. Book a free telephone consultation at https://www.biocare.co.uk/nutrition-consultation, call us Monday to Friday, 9am–5pm on 0121 433 8702, or email clinicalnutrition@biocare.co.uk.

Supporting the whole GLP-1 journey

GLP-1 and dual GIP/GLP-1 medications are changing weight management and, for many people, changing lives. But their effectiveness also creates a different challenge: making sure the food that remains is varied, nutrient-dense and appropriate to digestive tolerance.

The goal should not simply be a lower number on the scales. It is to support healthy body composition, digestive function, nutrient status and metabolic resilience throughout the journey.

When appetite becomes quieter, nutrition needs to become more intentional.

Key points summary:

• GLP-1 and dual GIP/GLP-1 medications can significantly reduce appetite and food intake, making nutrient density increasingly important.
• Common digestive effects include nausea, constipation, diarrhoea, bloating and delayed gastric emptying, with gallbladder complications and acute pancreatitis less common but important considerations.
• Reduced portions and dietary variety may increase the risk of nutrient insufficiency, particularly vitamin D, B vitamins, iron, zinc, magnesium and potassium.
• Protein intake and resistance exercise are key priorities for helping preserve muscle and healthy body composition during rapid weight loss.
• Supporting fibre intake, the gut microbiome, hydration, digestion and sustainable food habits can help people look after their wider health throughout their GLP-1 journey.

References:

1. Jackson SE, Brown J, Llewellyn C, Mytton O, Shahab L. Prevalence of use and interest in using glucagon-like peptide-1 receptor agonists for weight loss: a population study in Great Britain. BMC Medicine 2025 24:1. 2026;24(1):1-. doi:10.1186/S12916-025-04528-7
2. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021;384(11):989-1002. doi:10.1056/NEJMOA2032183;ISSUE:ISSUE:DOI
3. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022;387(3):205-216. doi:10.1056/NEJMOA2206038;WGROUP:STRING:MMS
4. Baggio LL, Drucker DJ. Biology of Incretins: GLP-1 and GIP. Published online 2007. doi:10.1053/j.gastro.2007.03.054
5. Saha B, Kamalumpundi V, Codipilly DC. GLP1 and GIP Receptor Agonists: Effects on the Gastrointestinal Tract and Management Strategies for Primary Care Physicians. Mayo Clin Proc. 2025;100(12):2228-2236. doi:10.1016/J.MAYOCP.2025.09.017
6. Smits MM, Van Raalte DH, Tonneijck L, Muskiet MHA, Kramer MHH, Cahen DL. GLP-1 based therapies: clinical implications for gastroenterologists. Gut. 2016;65(4):702-711. doi:10.1136/GUTJNL-2015-310572
7. Plummer MP, Jones KL, Cousins CE, et al. Hyperglycemia Potentiates the Slowing of Gastric Emptying Induced by Exogenous GLP-1. Diabetes Care. 2015;38(6):1123-1129. doi:10.2337/DC14-3091
8. Wettergren A, Wøjdemann M, Meisner S, Stadil F, Holst JJ. The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7-36 amide on gastric acid secretion in humans depends on an intact vagal innervation. Gut. 1997;40(5):597-601. doi:10.1136/GUT.40.5.597
9. He L, Wang J, Ping F, et al. Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials. JAMA Intern Med. 2022;182(5):513-519. doi:10.1001/JAMAINTERNMED.2022.0338
10. Sodhi M, Rezaeianzadeh R, Kezouh A, Etminan M. Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss. JAMA. 2023;330(18):1795-1797. doi:10.1001/JAMA.2023.19574
11. GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings on acute pancreatitis, including necrotising and fatal cases - GOV.UK. Accessed August 19, 2026. https://www.gov.uk/drug-safety-update/glp-1-receptor-agonists-and-dual-glp-1-slash-gip-receptor-agonists-strengthened-warnings-on-acute-pancreatitis-including-necrotising-and-fatal-cases
12. Kobylińska M, Antosik K, Decyk A, Kurowska K. Malnutrition in Obesity: Is It Possible? Obes Facts. 2022;15(1):19-25. doi:10.1159/000519503
13. Scott Butsch W, Sulo S, Chang AT, et al. Nutritional deficiencies and muscle loss in adults with type 2 diabetes using GLP-1 receptor agonists: A retrospective observational study. Obesity Pillars. 2025;15:100186. doi:10.1016/J.OBPILL.2025.100186
14. Sibal R, Balamurugan G, Langley J, Graham Y, Mahawar K. Macronutrient, Micronutrient Supplementation and Monitoring for Patients on GLP-1 Agonists: Can We Learn from Metabolic and Bariatric Surgery? Nutrients. 2025;17(23):3659. doi:10.3390/NU17233659
15. Tang H, Zhang B, Lu Y, et al. Risk of hair loss associated with glucagon-like peptide-1 receptor agonists in adults with type 2 diabetes: target trial emulation. BMJ. 2026;394:e100077. doi:10.1136/BMJ-2026-100077
16. Guo EL, Katta R. Diet and hair loss: effects of nutrient deficiency and supplement use. Dermatol Pract Concept. 2017;7(1):1. doi:10.5826/DPC.0701A01
17. Look M, Dunn JP, Kushner RF, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab. 2025;27(5):2720-2729. doi:10.1111/DOM.16275
18. Ceasovschih A, Asaftei A, Lupo MG, et al. Glucagon-like peptide-1 receptor agonists and muscle mass effects. Pharmacol Res. 2025;220:107927. doi:10.1016/J.PHRS.2025.107927
19. Harper ME, Dent RRM, Mcpherson R. High-Quality Weight Loss in Obesity: Importance of Skeletal Muscle. Diabetes. 2025;74(12):2191. doi:10.2337/DBI25-0003
20. Gofron KK, Wasilewski A, Małgorzewicz S. Effects of GLP-1 Analogues and Agonists on the Gut Microbiota: A Systematic Review. Nutrients. 2025;17(8):1303. doi:10.3390/NU17081303
21. Di Vincenzo F, Del Gaudio A, Petito V, Lopetuso LR, Scaldaferri F. Gut microbiota, intestinal permeability, and systemic inflammation: a narrative review. Intern Emerg Med. 2023;19(2):275. doi:10.1007/S11739-023-03374-W
22. Giacosa A, Guido D, Grassi M, et al. The effect of ginger (Zingiber officinalis) and artichoke (Cynara cardunculus) extract supplementation on functional dyspepsia: A randomised, double-blind, and placebo-controlled clinical trial. Evidence-based Complementary and Alternative Medicine. 2015;2015. doi:10.1155/2015/915087
23. Majeed M, Majeed S, Nagabhushanam K, et al. Evaluation of the Safety and Efficacy of a Multienzyme Complex in Patients with Functional Dyspepsia: A Randomized, Double-Blind, Placebo-Controlled Study. J Med Food. 2018;21(11):1120. doi:10.1089/JMF.2017.4172
24. Rao TP, Quartarone G. Role of guar fiber in improving digestive health and function. Nutrition. 2019;59:158-169. doi:10.1016/J.NUT.2018.07.109
25. Polymeros D, Beintaris I, Gaglia A, et al. Partially hydrolyzed guar gum accelerates colonic transit time and improves symptoms in adults with chronic constipation. Dig Dis Sci. 2014;59(9):2207-2214. doi:10.1007/S10620-014-3135-1
26. Suresh H, Zhou J, Ho V. The Short-Term Effects and Tolerability of Low-Viscosity Soluble Fibre on Gastroparesis Patients: A Pilot Clinical Intervention Study. Nutrients. 2021;13(12). doi:10.3390/NU13124298
27. Ruskovska T, Maksimova V, Milenkovic D. Polyphenols in human nutrition: from the in vitro antioxidant capacity to the beneficial effects on cardiometabolic health and related inter-individual variability - an overview and perspective. Br J Nutr. 2020;123(3):241-254. doi:10.1017/S0007114519002733
28. Aroda VR, Edelstein SL, Goldberg RB, et al. Long-term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study. J Clin Endocrinol Metab. 2016;101(4):1754-1761. doi:10.1210/JC.2015-3754
29. Fischer JAJ, Cherian AM, Bone JN, Karakochuk CD. The effects of oral ferrous bisglycinate supplementation on hemoglobin and ferritin concentrations in adults and children: a systematic review and meta-analysis of randomized controlled trials. Nutr Rev. 2023;81(8):904-920. doi:10.1093/NUTRIT/NUAC106
30. Kasbo J, Tuchweber B, Perwaiz S, et al. Phosphatidylcholine-enriched diet prevents gallstone formation in mice susceptible to cholelithiasis. J Lipid Res. 2003;44(12):2297-2303. doi:10.1194/jlr.M300180-JLR200
31. Liu CJ, Latham NK. Progressive resistance strength training for improving physical function in older adults. Cochrane Database Syst Rev. 2009;2009(3):CD002759. doi:10.1002/14651858.CD002759.PUB2
32. Budini B, Luo S, Tam M, et al. Trajectory of weight regain after cessation of GLP-1 receptor agonists: a systematic review and nonlinear meta-regression. EClinicalMedicine. 2026;93:103796. doi:10.1016/j.eclinm.2026.103796
33. Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38-48. doi:10.1001/JAMA.2023.24945